Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis
Retrospective analysis reveals ruxolitinib reduces corticosteroid use in cGVHD patients, suggesting safety benefits.
Key Points
This analysis aims to describe treatment patterns and corticosteroid management in patients with chronic graft-versus-host disease receiving ruxolitinib.
Retrospective analysis using administrative claims data from multiple health plans.
Included patients with chronic graft-versus-host disease receiving ruxolitinib after allogeneic hematopoietic stem cell transplantation.
Evaluated corticosteroid dosing, treatment length, and ruxolitinib dosage over time.
Patients received ruxolitinib for a median of 458 days with a median starting dosage of 10 mg/day.
90% of patients achieved discontinuation or reduction to low-dose corticosteroids by one year.
The median time from corticosteroid fill to discontinuation was 77 days.